1-20 of 29
Tomas Pika
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Tereza Popkova, Jakub Radocha, Martin Stork, Jiří Minařík, Jan Straub, Alexandra Jungova, Petr Pavlicek, Tomas Jelinek, Vladimir Maisnar, Ludek Pour, Tomas Pika, František Sedlák, Jan Soukup, Hana Plonkova, Ludmila Muronova, Viera Sandecka, Petra Krhovska, David Zihala, Roman Hajek
Journal: Blood
Blood (2024) 144 (Supplement 1): 1999.
https://doi.org/10.1182/blood-2024-211224
Published: 2024
Journal Articles

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Jiri Minarik, Luděk Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Stork Martin, Jan Straub, Vojtech Latal, Dominik Fric, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2024) 144 (Supplement 1): 2378.
https://doi.org/10.1182/blood-2024-200014
Published: 2024
Journal Articles

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Martin Stork, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Tomas Pika, Alexandra Jungova, Jan Straub, Jiri Minarik, Ivanna Boichuk, Dominik Fric, Denisa Novakova, Tereza Popkova, Lenka Polcerova, Vladimir Maisnar, Ludek Pour, Roman Hajek
Journal: Blood
Blood (2024) 144 (Supplement 1): 5156.
https://doi.org/10.1182/blood-2024-202002
Published: 2024
Journal Articles

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Jiri Minarik, Ludek Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Martin Stork, Jan Straub, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4733.
https://doi.org/10.1182/blood-2023-179299
Published: 2023
Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Capkova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Martin Mistrik, Jaroslav Bacovsky, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2021) 138 (Supplement 1): 2716.
https://doi.org/10.1182/blood-2021-148836
Published: 2021
Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek
Journal: Blood
Blood (2021) 138 (Supplement 1): 4894.
https://doi.org/10.1182/blood-2021-153978
Published: 2021
Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Jiri Minarik, MD PhD, Tomas Pika, MD PhD, Jakub Radocha, Alexandra Jungova, Jan Straub, MD, Tomas Jelinek, MD, Ludek Pour, MD, Petr Pavlicek, MD, Martin Mistrik, MD PhD, Lucie Brožová, MSc, Petra Krhovska, Katerina Machalkova, Pavel Jindra, MD PhD, Ivan Spicka, MD PhD Prof, Hana Plonkova, MD, Martin Stork, MD, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, MD, Lukáš Stejskal, MD, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, MD, Vladimir Maisnar, MD PhD MBA, Roman Hajek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3139.
https://doi.org/10.1182/blood-2019-128865
Published: 2019
Journal Articles

Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients:Â Analysis from Registry of Monoclonal Gammopathies (RMG)

Jakub Radocha, MD, Roman Hajek, Lucie Brozova, MSc, Ludek Pour, MD, Ivan Spicka, MDPhDProf, Jiri Minarik, MD PhD, Evzen Gregora, MD, Alexandra Jungova, Jan Straub, MD, Tomas Jelinek, Tomas Pika, Petr Pavlicek, MD, Viera Sandecka, MDPhD, David Vrabel, MSc, Adriana Heindorfer, Martin Stork, MD, Michal Sykora, Vladimir Maisnar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2019.
https://doi.org/10.1182/blood-2018-99-111882
Published: 2018
Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Jiri Minarik, MD PhD, Petra Krhovska, Tomas Jelinek, Alexandra Jungova, Martin Mistrik, MD PhD, Tomas Pika, MD PhD, Evzen Gregora, MD, Vladimir Maisnar, MD, Jan Straub, MD, Ludek Pour, MD, Lucie Brozova, MSc, Jaroslav Bacovsky, Hana Plonkova, Pavel Jindra, MD PhD, Petr Pavlicek, MD, Jakub Radocha, MD, Ivan Spicka, MDPhDProf, Martin Stork, MD, Vlastimil Scudla, Prof, MD CSc, Roman Hajek
Journal: Blood
Blood (2018) 132 (Supplement 1): 1959.
https://doi.org/10.1182/blood-2018-99-112046
Published: 2018
Journal Articles

Clinical Implications of MYD88 and CXCR4 in Patients with Waldenström's Macroglobulinemia

Martina Divoka, Tomas Pika, MD PhD, Lenka Krupkova, Monika Orviska, Romana Janska, Jiri Minarik, MD PhD, Tomas Papajik, MD prof
Journal: Blood
Blood (2018) 132 (Supplement 1): 5314.
https://doi.org/10.1182/blood-2018-99-112855
Published: 2018
Journal Articles

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Jiri Minarik, MD PhD, Edgar Faber, MD, Ludek Raida, MD PhD, Tomas Szotkowski, MD, Jaroslav Bacovsky, Tomas Pika, MD PhD, Ivana Skoumalova, MD PhD, Petra Krhovska, Jana Zapletalova, Mgr., PhD, Tomas Papajik, MD prof, Vlastimil Scudla, Prof, MD CSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 5749.
https://doi.org/10.1182/blood-2018-99-112115
Published: 2018
Journal Articles

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Martin Stork, MD, Sabina Sevcikova, PhD, Marta Krejci, Prof, MD PhD, Zdenek Adam, Prof. MD, Viera Sandecka, MD PhD, Vladimir Maisnar, MD TMD, MBA, Jakub Radocha, MD, Ivan Spicka, MD PhD Prof, Jan Straub, MD, Jiri Minarik, MD PhD, Tomas Pika, MD PhD, Alexandra Jungova, Evzen Gregora, MD, Petr Pavlicek, MD, David Vrabel, MSc, Jiri Jarkovsky, PhD, Lucie Brozova, MSc, Tomas Jelinek, MD, Roman Hajek, MD PhD, Ludek Pour, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5596.
https://doi.org/10.1182/blood-2018-99-114854
Published: 2018
Journal Articles

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

Clinical Trials & Observations
Tomas Pika, Ute Hegenbart, Pavla Flodrova, Bettina Maier, Christoph Kimmich, Stefan O. Schönland
Journal: Blood
Blood (2018) 131 (3): 368–371.
https://doi.org/10.1182/blood-2017-09-806463
Published: 2018
Journal Articles

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Jiri Minarik, MD PhD, Ludek Pour, MD PhD, Vladimir Maisnar, Prof, MD PhD, Ivan Spicka, MDPhD, Alexandra Jungova, MD, Hana Plonkova, Lucie Brozova, MSc, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Sabina Sevcikova, RNDr, PhD, Jakub Radocha, MD PhD, Vlastimil Scudla, Prof, MD CSc, Roman Hájek, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5414.
https://doi.org/10.1182/blood.V130.Suppl_1.5414.5414
Published: 2017
Journal Articles

Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup

Ruben Niesvizky, MD, Heinz Ludwig, MD, Andrew Spencer, MD, Hartmut Goldschmidt, MD, Tomas Pika, Maria-Victoria Mateos, Meletios A. Dimopoulos, Lifen Zhou, Amy S. Kimball, Thierry Facon, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1885.
https://doi.org/10.1182/blood.V130.Suppl_1.1885.1885
Published: 2017
Journal Articles

"Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases

Evangelos Terpos, MD PhD, Nadjoua Maouche, Jiri Minarik, MD PhD, Eirini Katodritou, Matthew W Jenner, Hana Plonkova, Maria Gavriatopoulou, Grant Vallance, Tomas Pika, Maria Kotsopoulou, Jaimal Kothari, Tomas Jelinek, Eftathios Kastritis, Robin Aitchison, Meletios A. Dimopoulos, Karthik Ramasamy, Roman Hajek
Journal: Blood
Blood (2017) 130 (Supplement 1): 3087.
https://doi.org/10.1182/blood.V130.Suppl_1.3087.3087
Published: 2017
Journal Articles

Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors

Jiri Minarik, MD PhD, Zuzana Hermanova, Jan Hrbek, Pavla Petrova, Patrik Flodr, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Miroslav Herman, Vlastimil Scudla
Journal: Blood
Blood (2016) 128 (22): 5603.
https://doi.org/10.1182/blood.V128.22.5603.5603
Published: 2016
Journal Articles

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Jorge J. Castillo, MD, Artur J. Jurczyszyn, MD PhD, Edvan Crusoe, MD MsC, Jacek Czepiel, MD, Julio Davila, MD, Angela Dispenzieri, MD, Marion Eveillard, PharmD, PhD, Mark A Fiala, BS, CCRP, Irene M. Ghobrial, MD, Alessandro Gozzetti, MD, Joshua Gustine, MPH, Roman Hájek, Vânia Hungria, MD PhD, Jiri Jarkovsky, MSc, PhD, David Jayabalan, BSMS, MSc, Jacob P. Laubach, MD, Barbara Lewicka, MD, Vladimir Maisnar, MD PhD, Elisabeth E. Manasanch, MD, Philippe Moreau, MD, Hareth Nahi, Ruben Niesvizky, MD, Claudia E. Paba-Prada, MD, Tomas Pika, MD PhD, Ludek Pour, MD PhD, John L Reagan, MD, Paul G Richardson, MD, Jatin J. Shah, MD, Ivan Spicka, MDPhD, Ravi Vij, MD, Anna Waszczuk, MD PhD, Morie A. Gertz, MD MACP
Journal: Blood
Blood (2016) 128 (22): 3276.
https://doi.org/10.1182/blood.V128.22.3276.3276
Published: 2016
Journal Articles

Multiple Myeloma and Bone Marrow Microenvironment Immunohistochemical Study of the Expression of 15 Proteins Related to Myeloma Bone Disease

Patrik Flodr, Pavla Latalova, Petra Pusciznova, Tomas Pika, Jaroslav Bacovsky, Vlastimil Scudla, Jiri Minarik
Journal: Blood
Blood (2015) 126 (23): 5318.
https://doi.org/10.1182/blood.V126.23.5318.5318
Published: 2015
Journal Articles

Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)

Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Meletios Dimopoulos
Journal: Blood
Blood (2015) 126 (23): 729.
https://doi.org/10.1182/blood.V126.23.729.729
Published: 2015